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ABSTRACT
Chronic diarrhea is a frequent presenting
symptom, both in primary care medicine and in
specialized gastroenterology units. It is esti-
mated that more than 5% of the global popu-
lation suffers from chronic diarrhea. and that
about 40% of these subjects are older than
60 years. The clinician is frequently faced with
the need to decide which is the best therapeutic
approach for these patients. While the origin of
chronic diarrhea is diverse, impairment of
intestinal barrier function, dysbiosis. and
mucosal micro-inflammation are being
increasingly recognized as underlying phe-
nomena characterizing a variety of chronic
diarrheal diseases. In addition to current phar-
macological therapies, there is growing interest
in alternative products such as mucoprotec-
tants, which form a mucoadhesive film over the
epithelium to reduce and protect against the
development of altered intestinal permeability,
dysbiosis, and mucosal micro-inflammation.
This manuscript focuses on chronic diarrhea in
adults, and we will review recent evidence on
the ability of these natural compounds to
improve symptoms associated with chronic
diarrhea and to exert protective effects for the
intestinal barrier.
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Chronic diarrhea is among the top five
causes of disability for all ages and
diseases.
Specific diets and mechanistic-targeted-
therapy, not devoid of adverse effects, are
only available for a subset of disorders.
If not treatable with specific therapy,
chronic diarrhea often needs long-term
symptomatic empiric antidiarrheal
therapy with opiate antidiarrheals and
bile acid sequestrants.
Impairment of the intestinal barrier with
changes in epithelial permeability, mucus
layer, and immune activation have been
increasingly implicated in the initiation
and perpetuation of a variety of diseases
associated with chronic diarrhea.
In this setting, mucosal protectors emerge
as a new alternative or complementary
therapy for a more efficient and safe
control of symptoms in disorders
associated with chronic diarrhea,
although additional studies are needed to
confirm if they are cost-effective in the
treatment of chronic diarrhea.
DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate under-
standing of the article. To view digital features
for this article, go to https://doi.org/10.6084/
m9.figshare.14039030.
INTRODUCTION
In adults, chronic diarrhea is a leading cause of
consultation in primary and secondary care [1],
and shows a significant negative impact on
health-related quality of life, high healthcare
utilization, and increased economic burden,
with direct and indirect costs estimated to reach
USD492 and 129 million, respectively, in the
United States in 1998 [2–4]. In 2019, the global
burden of disease study reported diarrheal dis-
eases, defined as three or more loose stools in a
24-h period, as the fifth ranked, causing 3.2%
(2.6–4.0) of disability-adjusted life-years
(DALYs) for all ages and diseases [5]. Moreover,
in 2019, 6.58 billion [95% uncertainty intervals
(UI) 6.05–7.14] incident cases and 99.0 million
(92.1–106) prevalent cases of diarrheal diseases
contributed to 1.53 million (1.09–2.22) deaths
and 80.9 million (65.4–103) DALYs. The most
DALYs occurred in children under 5 years [455
million (35.8–58.3)]. Virtually all patients will
experience diarrhea at some point in time, as
indicated by prevalence rates [ci’: 1312.4 per
100,000 (1218.9–1412.5); 9: 1286.7 per 100,000
(1192.4–1389.0)], and incidence rates [ci’:
87,105.0 per 100,000 (80131.1–94,668.2); 9:
85,249.4 per 100,000 (78,405.9–92,593.8)].
These rates were slightly higher among men
compared to females, while mortality rates [ci’:
20.7 per 100,000 (15.3–31.6); 9: 21.2 per
100,000 (12.6–31.4)] were slightly higher
among females compared to males [5].
Several definitions for chronic or persistent
diarrhea have been proposed over the years.
While patients’ concept of diarrhea is mostly
related to decreased stool consistency [6], doc-
tors’ concept is somewhat more pragmatic and
incorporates various terms including stool fre-
quency, consistency, volume or weight, and
duration of symptoms. Stool frequency ([3
bowel movements per day) is a commonly used
criterion [7–9]. Consistency refers to the water-
holding capacity of fecal solids, but this is dif-
ficult to quantify in clinical practice and stool is
predominantly water (60–85%), hence the
Bristol stool chart (BSFS) [10] for assessing con-
sistency is recommended [11]. In contrast, stool
weight or volume ([200 g/day) are not recom-
mended any more as a sole measure of chronic
diarrhea because up to 20% of patients with
watery diarrhea, who have a lower stool weight,
are not included in this definition, and because
stool weights vary greatly and ‘normal’ stool
volumes can easily exceed this value [12].
Although there is no consensus on the duration
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of symptoms, most authors would accept that
diarrhea persisting for longer than 4 weeks is a
reasonable limit to differentiate acute from
chronic diarrhea [2]. Therefore, a comprehen-
sive and pragmatic definition of chronic diar-
rhea incorporates all these elements [12]: the
presence of more than 3 stools per day; stool
consistency between types 5 and 7 on the BSFS;
and duration greater than 4 weeks.
Although difficult to estimate due to varia-
tions in definition and socio-demographic dif-
ferences across populations, in two population
surveys, Talley et al. reported a prevalence of
‘chronic diarrhea’, defined as loose, watery
stools often and/or stool frequency of more
than three stools per day, of between 4 and 5%
in a predominantly middle-aged white popula-
tion without the presence of abdominal pain,
and of between 7 and 14% in those with
abdominal pain (i.e., ‘functional bowel disease’)
[13]. Other studies have reported the combined
prevalence in a general population of irrita-
ble bowel syndrome with predominant diarrhea
(IBS-D) and functional diarrhea using the Rome
II questionnaire with figures of 3.3% in China
[14], 8.8% in Norway [15], and 13.5% in Canada
[16]. More recently, the prevalence of chronic
diarrhea in adults, defined as types 6 or 7 rating
on the BSFS, was 6.6% [95% confidence interval
(CI) 5.8, 7.4] in a nationally representative
sample of US adults [17]. In this study, after a
multivariable analysis, women were 1.7 times
more likely to have chronic diarrhea than men
(P = 0.001). The prevalence of chronic diarrhea
also increased with increasing age (P\0.001).
The most recent and largest epidemiologic
study performed by experts of the Rome Foun-
dation (https://theromefoundation.org/) inclu-
ded 73,076 adult respondents from 33 countries
in whom the diagnosis of IBS-D and functional
diarrhea was raised in the internet survey
(54,127 respondents) in 1.2% (1.1–1.3) and 4.7
(4.5–4.9), respectively [18]. In this study,
prevalence rates were substantially increased for
women with IBS-D and for men with functional
diarrhea, and health-related quality of life was
lower compared to those without these
disorders.
Chronic diarrhea has a broad differential
diagnosis, including both organic and
functional disorders of the gut, as well as a
growing list of drugs/herbal medications and
systemic disorders like diabetic neuropathy or
systemic sclerosis [1, 12, 19, 20]. Among organic
gut disorders, the main causes include infec-
tion, particularly persistent travelers’ diarrhea,
celiac disease, inflammatory bowel disease,
microscopic colitis, bile acid-induced diarrhea,
small intestinal bacterial overgrowth, carbohy-
drate malabsorption, exocrine pancreatic
insufficiency, bowel resection, radiation enteri-
tis, and colon cancer [21, 22]. Among func-
tional bowel disorders, functional diarrhea and
IBS-D are the leading disorders associated with
chronic diarrhea.
Management of chronic diarrhea depends
greatly on the identification of the causative
problem and comprehension of the underlying
pathophysiology, which usually relies on a
work-up for chronic diarrhea including personal
and family history, careful review of current
medications, physical examination, laboratory,
microbiological and hydrogen breath tests, and
imaging and endoscopic techniques [22]. When
the cause is identified, specific diet and therapy
aimed at the underlying pathophysiology are
initiated. If not treatable with specific therapy,
chronic diarrhea often needs long-term symp-
tomatic empiric antidiarrheal therapy, where
opiate antidiarrheals and bile acid sequestrants
remain as the mainstay, to mitigate symptoms
in most patients. However, long-term use of
these drugs may lead to misuse and abuse,
which has been related to serious heart prob-




al), and to common side effects and interference
with nutrient, vitamin, and drug absorption in
the case of cholestyramine https://www.drugs.
com/sfx/cholestyramine-side-effects.html).
Definition of Mucoprotectans
and Rationale for Their Use
in the Management of Chronic Diarrhea
Antidiarrheal drugs can be broadly defined as
agents that minimize the symptoms of diarrhea
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by improving stool consistency, reducing stool
frequency, or reducing stool weight by specific
or ill-defined/nonspecific mechanisms of action
[23]. The category of agents used for nonspecific
treatment of diarrhea includes adsorbents,
minerals, stool texture modifiers, and muco-
protectants that work intraluminally to modify
enteric contents.
A recent review and one meta-analysis report
the clinical efficacy of gelatin tannate (GT) [24],
xylogucan (XG), and other mucoprotectants
[25] for acute diarrhea in children and adults.
Therefore, this review focuses on chronic diar-
rhea in adults, and on the rationale for using
mucoprotectants as an alternative or comple-
mentary therapy for dealing with chronic diar-
rhea and major associated symptoms.
Mucoprotectans are products that share the
ability of creating a film-forming barrier over
the intestinal mucosa, helping to reduce the
Fig. 1 Mechanism of action of mucoprotectants. When
the mucus layer is damaged, access by pathogens, toxins,
allergens, and irritants across the intestinal barrier is
granted, which may enhance intestinal epithelial perme-
ability and inflammatory and immune responses of
resident immunocytes within the lamina propria. This
response, in turn, may lead to further distortion of
intestinal permeability and perpetuation of mucosal low-
grade inflammation, increasing apposition/communication
between immune cells, such as mast cells and plasma cells,
and nerve endings, neuronal plasticity, and regeneration
affecting the enteric nervous system (ENS) and afferent
routes to the central nervous system (CNS). Mucopro-
tectans like xyloglucan and gelatin tannate share mucoad-
hesive properties and the ability of creating a film-forming
barrier over the intestinal mucosa or protect the mucus
layer, helping to preserve intestinal permeability and avoid
or decrease mucosal inflammation, reducing the effect of
noxious agents on the intestinal barrier. Other molecules,
such as bismuth subsalicylate or smectite, may protect the
mucus layer via complex mechanisms
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effect of pathogens and to improve the function
of the intestinal barrier (Fig. 1). Several muco-
protectant products, classified as medical devi-
ces classes IIa or III, have been approved in
European countries, Israel, and Turkey for the
restoration of the physiological functions of the
intestinal wall and the treatment of diarrhea.
Similarly, GT has been approved as a drug or as
intermediate agent for the treatment of diarrhea
in Mexico, and in some countries in Africa and
south-east Asia. Other agents, such as bismuth
subsalicylate (BSS) and smectite, may also show
barrier-enhancing properties and, therefore, are
included in this review.
The intestinal barrier consists of a series of
contiguous layers, beginning on the lumenal
surface with the commensal microbiota and the
mucus layer, extending to the columnar
epithelium and extracellular matrix which lie
beneath them, and, ultimately, to the lamina
propria along with its constituent blood and
lymph vessels as well as intrinsic and extrinsic
nerve terminals. Enterocytes are characterized
by their apical brush border membrane, shaped
by * 1000 microvilli that cover the surface of
each cell. Each microvillus is 1–2 lm long and
has a diameter of 100–150 nm [26], rendering a
physical and functional barrier with an area of
exposure of 30–40 m2 [27]. This barrier separates
the intestinal lumen from the internal milieu,
secreting antimicrobial peptides and restricting
the passage of potentially harmful or antigenic
molecules across it, while maintaining nutrient
and electrolyte absorption, the transport of
macromolecules, and the control of inflamma-
tion [28]. Considerable evidence now supports
the existence of multidirectional communica-
tion between these layers [29].
A viscoelastic mucus gel layer with
hydrophobic and surfactant properties, secreted
by the goblet cells, covers the entire intestinal
mucosal surface [30]. Normal mucus is totally
transparent and microscopically invisible, as it
is made up of more than 98% water, the rest
being glycosylated proteins (mucins) and gly-
colipids. In the small and large intestines,
mucin 2 (MUC2) is the most abundant mucus
protein secreted by the goblet cells. Intestinal
epithelial cells also express transmembrane
mucins (MUC1, MUC3, MUC4, MUC12,
MUC13, MUC17, and MUC21) [26] that remain
attached to the apical surface and form the
glycocalyx together with glycolipids and
are[80% carbohydrate [30]. Secretory mucins
contain cysteine-rich sequences, located in the
– and C-terminal regions, which allow the for-
mation of disulfide bridges to form large poly-
mers that are of paramount importance for
protection of the gastrointestinal tract. Recent
investigations have shown that mucus is
resynthesized almost two times in the colon
during the average lifetime of gastrointestinal
epithelial cells [31], which is the organ with the
highest turnover rate in the body, estimated to
be between 3 and 5 days [32]. The protein
turnover of both epithelial cells and mucus in
the gastrointestinal tract is coordinated by the
microbiota [31]. Other components of mucus
include phospholipids, while other major
mucus proteins are secreted by the goblet cells,
including calcium-activated-1, Fc globulin
binding protein, and zymogen granule protein
16 [33], plus a variety of trefoil factors and other
antimicrobials, such as secretory IgA [34],
cathelicidins, lysozyme, and defensins pro-
duced by enterocytes and Paneth cells [35].
The distal colonic mucus can be divided into
an outer layer, colonized by bacteria, and a
mostly sterile inner layer. In the distal colon,
the inner mucus layer is dense and firmly
attached to the epithelium, which is approxi-
mately 50–100 lm thick, with an outer layer,
which is loose and movable, and about
700–800 lm thick in rats and humans
[33, 36, 37]. The small intestine has only one
mucus layer, which is much thinner than the
mucus layer in the large intestine (Fig. 2a, b). In
the cecum, it seems that there are breaches in
the mucus layer that may allow contact
between bacteria and epithelial cells, similar to
what happens in inflammatory bowel disease
[38].
The mucus layer prevents adhesion and
invasion by pathogenic microbes, and repre-
sents the habitat for the commensal gut bacteria
that also help to limit the colonization by
pathogenic microorganisms. Mucus helps to
regulate gut permeability and protects the
epithelial lining from luminal shear forces, the
toxic effects of dietary components, various
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chemicals, and radiation, as well as the impact
of antigens present in the intestinal lumen
[39, 40]. The mucus layer also contributes to the
retention of mucosal secretions containing
digestive enzymes and helps to sustain epithe-
lial hydration [41]. Mucus seems to enhance
oral tolerance by imprinting dendritic cells with
anti-inflammatory properties [42], participates
in epithelial renewal, differentiation, and
integrity, and also interacts with other biologi-
cal processes [43]. The importance of the mucus
layer is reflected in studies performed in MUC2
knockout mice, in which bacteria are in direct
contact with the epithelium leading to
increased intestinal permeability and the spon-
taneous and aggravated chemically-induced
development of colonic macroscopic
inflammation [44–46]. Similarly, in patients
with active ulcerative colitis, the inner mucus
layer is highly penetrable to bacteria [45, 46].
The small intestine is more exposed to the
intestinal bacteria, as the mucus layer is unat-
tached and permeable. However, fewer
microbes reside in the small intestine [47] due
to the fast transit time (0.5–5 h) and a high
concentration of antimicrobial peptides.
Just beneath the mucus layer, epithelial cells
remain tightly sealed at the basolateral surface,
the paracellular space, by means of the apical
junctional complex [48]. This complex is com-
posed of tight junctions (TJs), adherens junc-
tions (AJs), and desmosomes. Three
transmembrane proteins are common to all TJs:
claudins, MARVEL domain proteins, and
Fig. 2 Ultrastructural images of a normal mucus layer in
the rat ileum and colon. a Representative electron scanning
micrograph aspect of the mucus layer of the terminal ileum
of an adult Wistar rat (magnification 9397). (Courtesy
Dr. Maria Vicario.) b Representative electron scanning
micrograph aspect of the mucus layer of the colon of an
adult Wistar rat (magnification 9500). (Courtesy Dr.
Maria Vicario)
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junctional adhesion molecules (JAMs) [49]. The
claudin family consists of 26 members which
regulate paracellular permeability in the gas-
trointestinal tract. Among claudins, claudin 2
and interleukin (IL)-13 regulate the pore path-
way to form size (4–5 Å at the villus tip; 20 Å at
the base) and charge selective ion channels with
high capacity of transport [50]. Claudin-2
expression results in increased paracellular
Na? and K? conductance and water flux with-
out any effect on Cl- conductance or paracel-
lular flux of larger solutes, including mannitol,
lactulose, and 4 kD dextran[51]. The tight-
junction-associated marvel proteins occludin,
tricellulin, and marvelD3 are tetra-membrane
spanning proteins that regulate the recruitment
of signaling complex proteins to TJs, and
cooperate in the development and regulation of
macromolecular flux through the leak pathway
along with zonula occludens (ZO)-1, ZO-2, and
ZO-3, and cingulin [46, 52]. JAM-A, -B, and -C
are similar to immunoglobulin-G and may play
important roles in barrier formation and sig-
naling to circulating cells. AJs are located below
TJs and are mainly composed of e-cadherin,
catenin, and actin filaments. Alterations in
intestinal permeability have been linked to the
disappearance of key structural proteins of the
intestinal epithelial barrier, and to be charac-
teristic features of several chronic inflammatory
disorders, including inflammatory bowel dis-
ease, celiac disease, intestinal graft versus host
disease, critically ill patients, enteric infections,
and infestations, human immunodeficiency
virus infection, and acquired immune defi-
ciency syndrome, IBS-D, asthma, autism,
Parkinson’s disease, multiple sclerosis, eczema,
psoriasis, eosinophilic esophagitis, environ-
mental enteropathy, kwashiorkor, fibromyalgia,
depression, chronic fatigue syndrome, multi-
organ failure syndrome (shock, burns, trauma),
non-alcoholic fatty liver disease, alcoholic cir-
rhosis, obesity, metabolic syndrome, pancreati-
tis, and rheumatoid arthritis, among others
[53].
When understanding the concept of low-
grade mucosal inflammation associated with
disorders of chronic diarrhea, it is important to
again consider the histological structure of the
gut wall. The deepest layer of the intestinal
barrier is the lamina propria that contains
effector cells of both adaptive and innate
immune systems, T and B lymphocytes, IgA-
secreting plasma cells, mast cells, dendritic cells,
and macrophages. The loss of epithelial integ-
rity facilitates antigen, chemical, and toxin
penetration into the lamina propria, which
triggers immunological responses that, in turn,
increase epithelial permeability to luminal
content, thereby promoting inflammation.
Indeed, several common gastrointestinal and
systemic disorders associated with chronic
diarrhea share alterations in the gut epithelial
barrier, leading to abnormal intestinal perme-
ability, detachment of mucous layer, intestinal
dysbiosis, and, ultimately, low-grade mucosal
inflammation [33, 54]. Numerous studies have
provided evidence of increased numbers of
immunocytes in the lamina propria of diarrheal
diseases (mainly mast cells, eosinophils, and T
cells), such as IBS-D, ulcerative colitis, or
microscopic colitis [55–58].
In addition to infectious agents, there are
several predisposing factors for mucus damage
and intestinal leakiness that are commonly
involved in the development of chronic diar-
rhea and mucosal inflammation. Among these,
environmental stress, pregnancy, endurance
exercise, drugs and antibiotics, genetic suscep-
tibility, alcohol, and western diet, particularly
dietary emulsifiers and surfactants in food
additives, should be considered when evaluat-
ing and treating patients with chronic diarrhea
[33, 59–64].
Therefore, agents such as mucoprotectans,
due to their mucoadhesive and film-forming
barrier characteristics, may offer advantages for
the prevention of barrier abnormalities and
restoration of the mucus layer and altered
intestinal permeability to reduce mucosal
inflammation and gut mucosal homeostasis.
MUCOPROTECTANTS
Bismuth Subsalicylate
BSS is an insoluble salt of salicylic acid and
trivalent bismuth that was first FDA-approved
in 1939 and can be considered as a mucosal
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protector with approved indications for the
treatment of diarrhea, heartburn, indigestions,
nausea, and stomach upset [65]. The mecha-
nism of action is complex and partly unknown,
and involves the gastric hydrolysis into bis-
muth, and salicylic acid [66]. The salicylate
compound is almost completely absorbed into
the bloodstream, while bismuth remains in the
lumen of the gastrointestinal tract to form other
bismuth salts [67]. These bismuth salts show
bactericidal and antimicrobial activity [66, 68],
prevent bacteria from binding and growing on
the mucosal cells, inhibit intestinal secretions,
promote fluid, sodium, and chloride absorption
[69], reduce inflammation via cyclooxygenase
inhibition [70, 71], and decrease proliferative
actions of non-amidated gastrins in the rectal
mucosa of Sprague–Dawley rats and mice [72],
playing a major role in combating diarrhea.
Xyloglugan
XG is a non-ionic, water-soluble, high molecu-
lar weight branched polysaccharide hemicellu-
lose (MW: 1331 Kda) [73] that carries xylose and
galactosyl–xylose substituents, extracted from
the most abundant source of XG and soluble
fiber in nature, the seeds of the tamarind tree
(Tamarindus indica) [74, 75] (Fig. 3). XG is non-
toxic, edible, biocompatible, bioavailable, with
versatile use in foods, and resistant to digestive
enzymes, reaching the colon unaltered, where it
is partially broken down to oligosaccharides by
bacterial endo-ß-glucanases, followed by bacte-
rial fermentation of oligosaccharides [76–78].
The ‘mucin-like’ molecular structure of XG is
known to possess mucomimetic, mucoadhesive,
and pseudo-plastic properties [73, 79]. In the
gut, it acts as a film-forming barrier over the
intestinal mucosa, helping to reduce perme-
ability changes and invasion by pathogens like
E. coli and to decrease cholera toxin-induced
intestinal secretion in Caco2/goblet cells
[80–82], preserving tight junctions [75], and
binding consistently to MUC1 in molecular
docking studies and decreasing the expression
of MUC1 and MUC2, as shown in mice treated
with dextran sodium sulfate (DSS) [73]. Both
XG and GT pretreatment reduced the severity of
lipopolysaccharide (LPS)/induced mucosal
inflammation and jejunal hyperpermeability in
male Wistar rats, although they did not prevent
LPS-induced occludin and JAM-A down-regula-
tion. Further, GT and XG limited bacterial
mucus layer invasion and contact between
bacteria and intestinal epithelium [83]. XG is
often combined with gelatin or gelose to pro-
long its availability within the intestine, but
showing similar protective effects as XG alone
on barrier function and intestinal inflammation
in rats after LPS administration [84] and Sal-
monella enterica and Enterococcus hirae infections
[85]. In preliminary results, a single intracolonic
administration combination of XG with Bifi-
dobacterium animalis was found to be effective in
inducing mucosal healing in patients with
ulcerative colitis [86]. The combination of XG,
pea proteins, and tannins from grape xylo-
oligosaccharides also offered protection against
stress-induced visceral hypersensitivity and
intestinal hyperpermeability in rats [87].
Fig. 3 Basic molecular structure of hemicellulose. Xyloglu-
can from tamarind seeds consists of four types of
oligosaccharides as repeating units, commonly as heptasac-
charides [155]. The monomer unit contains three types of
sugars: xylose, galactose,? and glucose. The configuration
of this polysaccharide gives the product a ‘‘mucin-like’’




GT is a complex of tannic acid (penta-m-digal-
lolyl glucose) and gelatin which forms electro-
static bonds with mucin creating a protein-
based biofilm on the intestinal mucosa [88, 89].
Gelatin is a collagen derivate, which is ingested
as a powder that is insoluble at gastric acidic pH,
and which becomes a gelatin with the increase
of pH over 5.5 [90]. This complex enters the
intestine unaltered, increasing the epithelial
resistance against E. coli infection [91], helping
to restore the normal physiology of barrier
function, also reducing inflammation in
response to lipopolysaccharide administration
in rats [92]. GT also helps to restore the mucus
layer and to modulate the intestinal microbiota
in the DSS-induced model of murine colitis [93],
and in Caco cells [94], where it acts in part by
preventing the release of intercellular adhesion
molecule-1, IL-8, and tumor necrosis factor-a
induced by LPS [95]. Furthermore, the astrin-
gent properties of tannins allow the precipita-
tion of pro-inflammatory molecules from the
intestinal mucus and their fecal elimination
[96, 97]. Together, these effects may explain, at
least in part, the protective effect of GT on
intestinal barrier function.
Dioctahedral Smectite or Diosmectite
Diosmectite (DS) is a medicinal clay and a pro-
duct frequently recommended over-the-counter
in Eastern European countries [98], France [99],
and China [100] as an adjuvant therapy in
children and adults with acute diarrhea. It is
administered to reduce stool output, providing
symptomatic relief, and possibly preventing
dehydration [101]. It is formed from sheets of
aluminum and magnesium silicate. The mech-
anism of action is thought to be the result of:
anti-inflammatory activity; modifications of the
rheological characteristics of the gastrointesti-
nal mucus barrier to reduce penetration of tox-
ins and adsorptive properties; reduction of
intestinal permeability and apoptosis; and
improved intestinal epithelial cells prolifera-
tion, via modulation of IL-8, transforming
growth factor, extracellular signal-regulated
kinase , and protein kinase B signaling path-
way, and MUC2 expression [102, 103], thereby
reducing stool output and stress-induced vis-
ceral hypersensitivity. These mechanisms have
been replicated, mainly in vitro, in Caco-2 and
HT-29 cell lines, and in vivo in rodent and
piglets animal models [104–109], and the results
may be improved by combination with Lacto-
bacillus acidophilus [110].
METHODS
We searched MEDLINE and EMBASE via OVID,
from 1977 to January 2021 using a combination
of MeSH terms, EMTREE terms, and keywords
developed for each database. We also conducted
a search for all English language articles, sys-
tematic reviews, meta-analysis, conference pro-
ceedings, and abstracts in relevant scientific
meetings, on the epidemiology, etiology, phys-
iopathology, and management of chronic and
persistent diarrhea in immunocompetent indi-
viduals using the search terms: persistent diar-
rhea, chronic diarrhea, infectious diarrhea, enteric
infection, epidemiology, treatment, management,
guidelines, adults, mucus, intestinal permeability,
xyloglucan, gelatin tannate, bismuth subsalicylate,
diosmectite, smectite, and mucoprotectans. Bibli-
ographies of review and meta-analysis articles
were used to identify additional sources. Web-
sites for the US Centers for Disease Control and
Prevention, US Food and Drug Administration,
and World Health Organization were also
accessed for any additional information related
to this topic.
All studies were reviewed and summarized by
two independent reviewers to determine their
eligibility. Only primary studies conducted on
human adult subjects (18 years and older) pre-
senting with chronic diarrhea with observed
parameters directly related to diarrhea were
included.
This article is based on previously conducted
studies and does not contain any new studies
with human participants or animals performed
by any of the authors.
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RESULTS
Available studies were read and summarized,
and the study design, population, parameters
observed, and outcomes documented (Table 1).
BSS in Chronic/Persistent Diarrhea
in Adults
Chronic/persistent diarrhea occurs in approxi-
mately 3% of individuals traveling to develop-
ing countries, and in more than 10% of patients
suffering acute infectious enteritis [111]. The
microbiologic causes include parasitic (e.g.,
Giardia, Cryptosporidium, Schistosoma mansoni)
and bacterial (e.g., enteroaggregative E. coli,
Shigella, Campylobacter, Salmonella) pathogens
[21]. BSS has demonstrated effectiveness in the
prevention of traveler’s diarrhea [112, 113] and
in the treatment of acute diarrhea [114]. For
traveler’s diarrhea in adult patients with mild
symptoms [115, 116], BSS has been shown to
decrease stool frequency, time to symptom
relief, need for intravenous rehydration, and
work absenteeism in comparison to placebo or
antibiotics. However, there are no studies on
the effect of BSS on chronic/persistent diarrhea
after acute infectious enteritis. Considering the
efficacy of BSS in the management of acute
diarrhea and the increasing prevalence of
postinfective diarrhea and antibiotic resistance
among diarrheal pathogens [117], it would be
wise to perform additional studies to evaluate
the efficacy and safety of BSS in the manage-
ment of postinfective diarrhea.
Both IBS-D and microscopic colitis (MC) are
common causes of chronic diarrhea in adults.
One open-label study showed that the combi-
nation of BSS and spasmolytics during 3 weeks
improved bowel symptoms in IBS-D, including
diarrhea in a small group of patients (n = 20)
[118]. BSS is recommended by the 2016 AGA
guideline as a second-line therapy for MC when
budesonide is unable to be used, either due to
cost or adverse effects [119]. This is based on
two small studies that found that treatment
with BSS for 8 weeks reduced the frequency and
weight of bowel movements, improved stool
consistency, and decreased tissue inflammation
in patients with MC [120, 121]. A retrospective
study showed complete response in 53% of
patients and partial response in 28% of patients
taking three tablets (262 mg each) of bismuth
salicylate three times a day [122]. Chronic
diarrhea is a common manifestation of a variety
of cancers that can be attributed to adverse
effects of treatments, radiotherapy, surgery, and
infection. One prospective pilot study revealed
that the duration of diarrhea experienced by
lymphoma patients receiving melphalan
chemotherapy was decreased as compared to
the placebo group, while this did not happen in
multiple myeloma patients irrespective of
treatment [123]. However, this article has been
retracted by the journal because major findings
could not be replicated upon reanalysis [124].
Though anecdotical, a recent case report
showed a good temporal response of diarrhea in
a COVID-19-positive Crohn’s disease patient
treated with BSS [125].
Limitation to its use in chronic diarrhea
relate to the number of daily tablets needed to
treat, to the compromised absorption of other
compounds and to the restricted use in patients
with renal impairment [126]. BSS is safe, rela-
tively cheap, and has limited side effects, yet
tinnitus, blackened tongue and dark feces are
not unusual in short-term therapy and make its
use undesirable for some patients [124].
Although quite rare, the most concerning
adverse effect of BSS is salicylate and bismuth
non-eurotoxicity that primarily occurs in
patients who have taken bismuth subsalicylate
inappropriately, whether through an overdose
or for extended periods of time [127].
XG in Chronic/Persistent Diarrhea
in Adults
Several clinical trials have been reported on the
efficacy of XG in the treatment of acute diarrhea
in children [128, 129] and adults [81]. However,
there are limited data regarding its use in
chronic diarrhea. One recent multicenter, dou-
ble-blind, placebo-controlled, randomized,
crossover clinical trial evaluated the efficacy
and safety of a commercially available combi-










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































grape seed extract, and xylo-oligosaccharides in
patients with IBS-D [130]. The study showed
that, at day 28, the therapeutic combination of
XG normalized stool consistency in a signifi-
cantly higher proportion of patients as com-
pared to placebo (87 vs. 0%; P = 0.0019), and,
after the crossover, at day 56, the effect of XG
was reproduced (93% vs. 23%; P = 0.0001). This
benefit remained present at day 116 of follow-
up (67% vs. 13%) with no significant adverse
events. In most cases, remission of diarrhea
symptoms was apparent within 15 days of
starting treatment. A therapeutic gain was also
observed for abdominal pain and bloating.
Another study assessed other precursor
medical device containing other film-forming
agents, reticulated proteins, in combination
with a prebiotic mixture of vegetable oligo- and
poly-saccharides, in patients with IBS-D [131].
After 8 weeks of treatment, remission of diar-
rhea, defined as two or less non-watery stools
emissions per day (stool of type 5 or less on the
BSFS) was achieved in 76.19% in the active
group vs. 47.69% in the placebo group
(P\0.0001). In addition, bowel frequency
(P = 0.001), abdominal pain (P = 0.0167), and
flatulence (P = 0.0373) were all significantly
improved in patients in the active group as
compared with placebo at 56 days of follow-up.
A significant increase in the quality of life was
also detected in the active group at day 56
(P\0.0001 vs. placebo). No major adverse
events were recorded and treatment was well
tolerated.
In conjunction, these results support the use
of the use of XG reticulated protein and oligo-
and polysaccharides in the treatment of chronic
diarrhea, at least in IBS-D patients.
GT in Chronic/Persistent Diarrhea
in Adults
Similar to XG, several clinical trials have been
reported on the use of GT in the treatment of
acute diarrhea in children [90, 132–138], and
adults [139, 140], with conflictive results on the
efficacy as published in three different meta-
analysis [24, 141, 142]. Unfortunately, we have
not found studies with GT in adult patients
with chronic diarrhea. Although, the combina-
tion of GT and tyndallized probiotics has been
claimed as highly effective in the treatment of
moderate and prolonged diarrhea [143, 144],
there is so far no clinical evidence to support
this. However, a randomized, double-blinded,
placebo-controlled, clinical trial investigating
the efficacy and safety of gelatin tannate and
tyndallized acid lactic bacteria versus placebo
administered to adult patients with chronic
diarrhea with dysbiosis is ongoing
(ISRCTN63068134).
DS in Chronic/Persistent Diarrhea
in Adults
The potential utility of DS in the management
of chronic diarrhea is based on its efficacy as
shown in a number of open [145–147] and
randomized double-blind, placebo-controlled
[104, 148–151] clinical trials performed mostly
in children with acute diarrhea, and high-
lighted in a recent Cochrane review [101]. One
open, randomized, controlled trial compared
the efficacy of 3 g of dioctahedral smectite/8 h
versus a commercial mixture of probiotics con-
taining L. bifidus, acidophilic lactobacilli and
Enterococcus in the management of chronic
functional diarrhea in a large group of partici-
pants, during 28 consecutive days [152]. As
soon as 2 weeks from the beginning of treat-
ment, smectite was shown to be significantly
superior to probiotics in reducing bowel fre-
quency (P = 0.007), and this gain was main-
tained over the treatment period and during the
follow-up period of 2 weeks. A similar signifi-
cant benefit for smectite over probiotics was
shown for stool consistency at 2 weeks of
treatment and remained for the 28 days
(P = 0.001), but the benefit disappeared after
discontinuation. No serious adverse effects were
reported. Another prospective controlled ran-
domized trial study compared DS against lop-
eramide for 2 weeks in the management of
chronic functional diarrhea. This study showed
a similar efficacy of both drugs for the control of
diarrhea while DS was superior to loperamide in
the control of pain and bloating [153]. Another
randomized, double-blind, placebo-controlled
Adv Ther
trial, showed no benefit of DS over placebo in
improving bowel frequency, consistency,
urgency and mucus discharge in IBS-D after
8 weeks of treatment [154]. However, DS sig-
nificantly improved abdominal pain, bloating,
and the overall visual analogue scale score of
IBS. No serious adverse effects were reported.
However, three patients were hospitalized dur-
ing the trial (two in the placebo group because
of cellulitis and acute appendicitis; one in the
DS group because of renal stone). Constipation
was the most common effect related to DS
treatment, but its occurrence was not different
from placebo. Other recorded adverse effects
were similar in both groups: nausea, abdominal
pain, and dyspepsia.
SUMMARY AND CONCLUSIONS
There are many available drugs for the treat-
ment of chronic diarrhea. The majority of them
target specific mechanisms/pathways involved
in the origin of diarrhea. However, it is com-
mon for many disorders associated with chronic
diarrhea, particularly (but not only) for the very
prevalent IBS-D and functional diarrhea, that
their development involves multiple or
unidentified mechanisms. Among these mech-
anisms, the impairment of the intestinal barrier
with changes in epithelial permeability, mucus
layer, and immune activation deserves special
focus because they have been increasingly
implicated in the initiation and perpetuation of
a variety of diseases, thereby justifying the
emerging interest in the advent of new phar-
macological/non-pharmacological approaches
for the restoration of barrier function.
Much of this work relates to the use of
mucosal protectors, as a new alternative or
complementary therapy for a more efficient and
safe control of symptoms in disorders associated
with chronic diarrhea, mostly in IBS-D. The
objective of mucosal protection is to create an
artificial mechanical barrier over the mucosa, to
reduce contact/access between noxious aller-
gens, irritants, toxins, pathogens, and their
virulence factors and the mucosal immune sys-
tem, to prevent mucus damage and preserve
intestinal permeability. The need of these
barrier enhancers, some marketed as medical
devices, is also supported in the current context
of high levels of antimicrobial resistance and to
avoid long-lasting pharmacological treatments,
their adverse events, and frequent elevated
costs. In adults with chronic diarrhea, the
studies available to date suggest that these
mucoprotectants can be helpful, improving
stool frequency and consistency, and showing
beneficial effects on other symptoms such as
abdominal pain, bloating, and flatulence.
Importantly, they appear to be safe, with few
adverse events, although some caution is
advised on the chronic use of BSS and tannins
and on their potential interference with the
mechanism of action of other drugs. In addi-
tion, it is currently unclear whether the use of
mucoprotectans is cost-effective, partly because
some of them (xyloglucan, gelatin tannate, and
disomectite) are sold over the counter and not
covered by health insurance or public health
systems, and partly because the lack of high-
quality evidence. However, there are a number
of limitations to the available data. There is a
paucity of studies and several of them have been
criticized because they were reported only as
abstracts or posters, and many were observa-
tional in design and did not include a control
group, rendering a low quality of evidence due
to imprecision, inconsistency, and risk of bias
when defining diarrhea characteristics across
studies, yet this criticism may be limited due to
heterogeneity in some outcomes [142]. In
addition, the evidence provided relates mostly
to IBS-D, which may not be applicable to other
disorders with chronic diarrhea. Finally, it is
important to note here that, while some of
these products are marketed as mucoprotectans,
the mechanism by which they protect the
mucosa is not well established, just as it is not
well established that mucoprotection is the
mechanism by which chronic diarrhea is ame-
liorated. In conclusion, although mucopro-
tectans are promising, there is a clear need for
additional randomized controlled trials in large
and controlled populations assessing clinically
relevant outcomes to further explore their
effects and confirm their usefulness in the
treatment of chronic diarrhea. Microbiological
analysis of fecal and mucosal samples would
Adv Ther
also provide useful information about their
effects on intestinal microbiota, particularly in
patients with dysbiosis. In addition, clinical,
functional, and laboratory evaluation of their
effects on intestinal permeability and mucus
integrity is also warranted to ascertain their
in vivo ability to restore these functions and to
extend their use in the management of a variety
of gastrointestinal diseases associated with
‘leaky gut.’
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55. González-Castro AM, Martı́nez C, Salvo-Romero E,
et al. Mucosal pathobiology and molecular signa-
ture of epithelial barrier dysfunction in the small
intestine in irritable bowel syndrome. J Gastroen-
terol Hepatol. 2017;32:5363.
56. Cremon C, Gargano L, Morselli-Labate AM, et al.
Mucosal immune activation in irritable bowel syn-
drome: gender-dependence and association with
Adv Ther
digestive symptoms. Am J Gastroenterol. 2009;104:
392–400.
57. Bashashati M, Moossavi S, Cremon C, et al. Colonic
immune cells in irritable bowel syndrome: a sys-
tematic review and meta-analysis. Neurogastroen-
terol Motil. 2018;30(1):e13192.
58. Wouters MM, Vicario M, Santos J. The role of mast
cells in functional GI disorders. Gut. 2016;65:
155–68.
59. He J, Guo H, Zheng W, et al. Effects of stress on the
mucus-microbial interactions in the gut. Curr Pro-
tein Pept Sci. 2019;20:155–63.
60. Da Silva S, Robbe-Masselot C, Ait-Belgnaoui A, et al.
Stress disrupts intestinal mucus barrier in rats via
mucin O-glycosylation shift: prevention by a pro-
biotic treatment. Am J Physiol Gastrointest Liver
Physiol. 2014;307:G420–9.
61. Alonso C, Guilarte M, Vicario M, et al. Maladaptive
intestinal epithelial responses to life stress may
predispose healthy women to gut mucosal inflam-
mation. Gastroenterology. 2008;135(163–172):e1.
62. Pals KL, Chang RT, Ryan AJ, et al. Effect of running
intensity on intestinal permeability. J Appl Physiol
(1985). 1997;82:571–6.
63. Partridge D, Lloyd KA, Rhodes JM, et al. Food
additives: assessing the impact of exposure to per-
mitted emulsifiers on bowel and metabolic health-
introducing the FADiets study. Nutr Bull. 2019;44:
329–49.
64. Chelakkot C, Ghim J, Ryu SH. Mechanisms regu-
lating intestinal barrier integrity and its pathologi-
cal implications. Exp Mol Med. 2018;50:103.
65. Budisak P, Abbas M. Bismuth Subsalicylate. 2020
Nov 26. In: StatPearls [Internet]. Treasure Island
(FL): StatPearls Publishing; 2020. PMID: 32809532.
66. Pitz AM, Park GW, Lee D, et al. Antimicrobial
activity of bismuth subsalicylate on Clostridium dif-
ficile, Escherichia coli O157:H7, norovirus, and
other common enteric pathogens. Gut Microbes.
2015;6:93–100.
67. Nwokolo CU, Mistry P, Pounder RE. The absorption
of bismuth and salicylate from oral doses of Pepto-
Bismol (bismuth salicylate). Aliment Pharmacol
Ther 1990;4:163–9.
68. Manhart MD. In vitro antimicrobial activity of bis-
muth subsalicylate and other bismuth salts. Rev
Infect Dis. 1990;12(Suppl 1):S11–5.
69. Gorbach SL. Bismuth therapy in gastrointestinal
diseases. Gastroenterology. 1990;99:863–75.
70. National Center for Biotechnology Information
(2021). PubChem Compound Summary for CID
16682734, Bismuth subsalicylate. Retrieved January
5, 2021 from https://pubchem.ncbi.nlm.nih.gov/
compound/Bismuth-subsalicylate. Accessed 13 Mar
2021.
71. Sheele J, Cartowski J, Dart A, et al. Saccharomyces
boulardii and bismuth subsalicylate as low-cost
interventions to reduce the duration and severity of
cholera. Pathog Glob Health. 2015;109:275–82.
72. Kovac S, Loh SW, Lachal S, et al. Bismuth ions
inhibit the biological activity of non-amidated
gastrins in vivo. Biochem Pharmacol. 2012;83:
524–30.
73. Periasamy S, Lin CH, Nagarajan B, et al. Mucoad-
hesive role of tamarind xyloglucan on inflamma-
tion attenuates ulcerative colitis. J Funct Foods.
2018;47:1–10.
74. Kozioł A, Cybulska J, Pieczywek PM, et al. Evalua-
tion of structure and assembly of xyloglucan from
tamarind seed (Tamarindus indica L.) with atomic
force microscopy. Food Biophys. 2015;10:396–402.
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